Objective: To verify the efficacy and safety of anti-angiogenesis therapy combined with endocrine therapy (ET) in a case of young hormone receptor (HR) positive advanced breast cancer (ABC) involving chest wall metastasis (CWM).
Method: We described a recent case of HR positive ABC receiving anti-angiogenesis therapy combined with ET and reviewed relevant literature regarding the efficacy and safety.
Results: Complete resolution of the CWM was perceived over the course of two months after initiation of treatment, with grade 2 proteinuria and grade 2 intracranial hemorrhage that was resolved with symptomatic and supportive treatment.
Conclusion: Anti-angiogenesis therapy combined with ET was highly effective for the breast cancer patient with CWM. However, adverse events deemed inevitable and vigilant monitoring from the beginning of treatment proved beneficial.